IMMUNOLOGICAL STATUS IN PATIENTS WITH CHRONIC DIFFUSE LIVER DISEASES ON THE BACKGROUND OF EPSTEIN–BARR VIRUS INFECTION
Abstract
Introduction. In regions with a high level of environmental pollution with xenobiotics or radionuclides, in modern conditions, there is a spread of chronic diffuse liver diseases, for which infectious mononucleosis, which causes the Epstein–Barr virus (EBV), is characteristic as a background pathology. Aim. To study the effect of bacterial lysate and phosphatidylcholine sodium glycyrrhizinate on the level of circulating immune complexes in patients with chronic diffuse liver diseases against the background of EBV infection. Materials and methods. Two groups of patients diagnosed with chronic diffuse liver diseases on the background of EBV infection were under observation — the group I (34 people) and the group II (32 people). Patients of the I-group received conventional treatment, patients of the I-group received bacterial lysate and sodium phosphatidylcholine glycyrrhizinate in addition to conventional treatment. In both groups of the examined patients, along with the generally accepted laboratory examination, the level of circulating immune complexes was determined. Results. As a result of the conducted studies, the positive effect of the proposed therapy on the humoral parameters of immunity was established, which was manifested by a decrease in the concentration of circulating immune complexes was determined, due to a decrease in the content of the most pathogenic mediummolecular and small-molecular fractions. Discussion. The data obtained indicate that the inclusion of bacterial lysate and phosphаtidylcholine sodium glycyrrhizinate in the course of treatment of patients with chronic diffuse liver diseases against the background of EBV causes the elimination of secondary immunodeficiency and normalization of immunological parameters, contributes to the normalization of immunological homeostasis, reduces the development of complications and reduces the frequency of immunodeficiency states in the period of convalescence. Conclusions. The use of bacterial lysate and phosphаtidylcholine sodium glycyrrhizinate in the treatment of patients with chronic diffuse liver diseases against the background of EBV infection contributes to the normalization of the content and fractional composition of circulating immune complexes (CIC), especially medium and small molecular fractions.
References
Акалаев Р.Н., Стопницкий А.А., Арипходжаева Г.З., Саидова М.К. Токсические поражения печени при острых отравлениях и эндогенной интоксикации. Вестник экстренной медицины. 2020;13(6):95–102.
Антипов М.О., Миндлина А.Я. Болезни органов пищеварения инфекционной и неинфекционной природы. Эпидемиологическая взаимосвязь. Эпидемиология и Вакцинопрофилактика. 2019;18(1):55–66. DOI: 10.31631/2073- 3046-2019-18-1-55-66.
Гундерман К.-Дж., Дроздзик М., Цыркунов В.М. Влияние эссенциальных фосфолипидов на течение неалкогольной и алкогольной жировых болезней печени. Гепатология и Гастроэнтерология. 2019;3(1):5–13. DOI: 10.25298/2616-5546-2019-3-1-5-13.
Демина О.И., Чеботарева Т.А., Мазанкова Л.Н., Тетова В.Б, Учаева О.Н. Клинические проявления инфекционного мононуклеоза при первичной или реактивированной герпесвирусной инфекции. Российский вестник перинатологии и педиатрии. 2020;65(1):37–44. DOI: 10.21508/1027-4065-2020-65-1-37-44.
Дроздова Н.Ф., Фазылов В.Х. Инфекционный мононуклеоз, обусловленный вирусом Эпштейна–Барр: клинико-патогенетические аспекты (обзор литературы). Вестник современной клинической медицины. 2018;11(3):59–65. DOI: 10.20969/VSKM.2018.11(3).59-61.
Оковитый С.В. Комбинированное применение гепатопротекторов. Лечащий врач. 2020;8:38–43.
Перфильева М.Ю., Соцкая Я.А. Уровень циркулирующих иммунных комплексов и их молекулярный состав у больных с вторичным иммунодефицитным состоянием на фоне рецидивирующей герпетической инфекции. Вестник скорой помощи. 2023;1-2(7-8):15–8.
Фролов В.М., Пересадин Н.А., Бойченко П.К. Диагностическое и прогностическое значение циркулирующих иммунных комплексов у больных. Врачебное дело. 1990;6:116–18.
Фролов В.М., Рычнев В.Е. Исследование циркулирующих иммунных комплексов их диагностическое и прогностическое значение. Лабораторное дело. 1986;3:159–61.
Ahumada-Cota R.E., Hernandez-Chiñas U., Milián-Suazo F., Chávez Berrocal M.E., Navarro-Ocaña A., Martínez-Gómez D. Effect and analysis of bacterial lysates for the treatment of recurrent urinary tract infections in adults. Pathogens. 2020;9(2):102. DOI: 10.3390/pathogens9020102.
Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57. DOI: 10.1002/hep.29367.
Cornberg M., Tacke F., Karlsen T.H. European Association for the Study of the Liver. Clinical Practice Guidelines of the European Association for the study of the Liver Advancing methodology but preserving practicability. J Hepatol. 2019;70(1):5–7. DOI: 10.1016/j.jhep. 2018.10.011.
Jurkiewicz D., Zielnik-Jurkiewicz B. Bacterial lysates in the prevention of respiratory tract infections. Otolaryngol Pol. 2018;72(5):1–8. DOI: 10.5604/01.3001.0012.7216.
Younossi Z.M. Non-alcoholic fatty liver disease — A global public health perspective. J Hepatol. 2019;70(3): 531–44. DOI: 10.1016/j.jhep.2018.10.033.
